dose trials doses superior variations
Research gap analysis derived from 2 medicine papers in our local library.
The gap
Higher doses (≥300 mg/day) have not consistently demonstrated superior anticancer benefits in randomized trials, and the reasons for dose-response variations are unclear.; 2016), was observed in some trials, yet the optimal dose and duration remain unclear.
Research trend
Emerging — attention growing, methods still coalescing.
Supporting evidence — 2 representative gaps
- Aspirin's Dual Role in Cancer: A Systematic Review of the Current Evidence (2026) · doi
Higher doses (≥300 mg/day) have not consistently demonstrated superior anticancer benefits in randomized trials, and the reasons for dose-response variations are unclear.
Keywords: higher doses consistently superior anticancer benefits randomized trials reasons dose response variations unclear - Efficacy and safety of oral doxycycline for acne vulgaris treatment: A systematic review and meta-analysis (2026) · doi
2016), was observed in some trials, yet the optimal dose and duration remain unclear.
Keywords: observed trials optimal dose duration remain unclear
Working on this gap? Publish with us.
Science AI Journal reviews manuscripts in under 15 minutes with 8 specialised AI reviewers calibrated on 23,000+ real peer reviews. Open access, CC BY 4.0.
Related gaps in medicine
- clinical training cannot collection discussThe paper references GPT-4-based AI agents for detection of antimicrobial resistance mechanisms (reference 35), but does not address how to …
- establish relationships infection functional demographicThe study population and demographic characteristics (age range, comorbidities, race/ethnicity, geographic origin) are not described in the …
- patient clinical actual validated diagnosisThe EU AI Act and GDPR do not fully address patient consent and data use complexities specific to clinical AI deployment. No framework has b…
- confirm growth within reproducibility nutrientThe two-phase cultivation strategy was successfully translated from static small-scale experiments to a 6.6% capacity STR bioreactor run due…